Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

Blood

Volumn 102, Issue 3, 2003, Pages 814-819

  Giebel, Sebastian ^b   Locatelli, Franco ^a   Lamparelli, Teresa ^b   Velardi, Andrea ^b   Davies, Stella ^b   Frumento, Guido ^b   Maccario, Rita ^b   Bonetti, Federico ^b   Wojnar, Jerzy ^b   Martinetti, Miryam ^b   Frassoni, Francesco ^b   Giorgiani, Giovanna ^b   Bacigalupo, Andrea ^b   Holowiecki, Jerzy ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN RECEPTOR; KILLER IMMUNOGLOBULIN LIKE RECEPTOR LIGAND; LIGAND; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ALLOIMMUNITY; ARTICLE; CLINICAL TRIAL; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOINCOMPATIBILITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MORTALITY; MULTICENTER STUDY; NATURAL KILLER CELL; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; SURVIVAL RATE;

EID: 10744230735     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0091     Document Type: Article

References (15)

1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990; 76:2421-2438.
2. Farad SS, Fehniger T, Ruggeri L, et al. Natural killer cell receptors: new biology and insights into graft versus leukemia effect. Blood. 2002;100: 1935-1947.
3. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-339.
4. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
5. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion. 2001;41:1299-1305.
6. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
7. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by bone marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461-466.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
9. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risk: new representations of old estimators. Stat Med. 1999;18:695-706.
10. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
11. Giebel S, Giorgiani G, Martinetti M, et al. Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing. Bone Marrow Transplant. 2003. In press.
12. Davies SM, Ruggeri L, DeFor T, et al. An evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood. 2002;100:3825-3827.
13. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98: 2942-2947.
14. Hayasaka Y, Takehashi K, Yagisawa T, et al. Immunological evaluation on ATG-F of its antibody specificity and the effect on graft rejection. Paper presented at: 28th Conference of the Japanese Transplantation Society; September 24-26, 1992; Osaka, Japan.
15. Karre K. Immunology: a perfect mismatch. Science. 2002;295:2029-2031.